CytoMed Therapeutics (GDTC) Enterprise Value (2023 - 2025)

CytoMed Therapeutics has disclosed Enterprise Value across 3 years of filings, most recently posting $14.5 million for Q4 2025.

• In Q4 2025, Enterprise Value fell 59.12% year-over-year to $14.5 million; the TTM figure through Dec 2025 stood at $14.5 million (down 59.12% YoY), while the FY2025 annual figure was $14.6 million, down 59.09% from the prior year.
• Enterprise Value came in at $14.5 million for Q4 2025 at CytoMed Therapeutics, down from $23.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $44.7 million in Q4 2023 to a low of $13.7 million in Q2 2023.
• Average Enterprise Value over 3 years is $24.4 million, with a median of $19.1 million recorded in 2024.
• The largest YoY upside for Enterprise Value was 54.5% in 2025 against a maximum downside of 59.12% in 2025.
• Over 3 years, Enterprise Value stood at $44.7 million in 2023, then dropped by 20.38% to $35.6 million in 2024, then sank by 59.12% to $14.5 million in 2025.
• Per Business Quant data, the three most recent Enterprise Value figures were $14.5 million in Q4 2025, $23.2 million in Q2 2025, and $35.6 million in Q4 2024.